- Lyra Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference TranscriptSep 26, 2023
- Lyra Therapeutics Inc at HC Wainwright Investment Conference - New York TranscriptSep 13, 2023
- Lyra Therapeutics Inc to discuss the topline results of the BEACON study Call TranscriptSep 12, 2023
- Lyra Therapeutics Inc at Jefferies Healthcare Conference TranscriptJun 07, 2023
- Lyra Therapeutics Inc at Bank of America Global Healthcare Conference TranscriptMay 10, 2023
- Lyra Therapeutics Inc at Jefferies London Healthcare Conference TranscriptNov 17, 2022
- Lyra Therapeutics Inc at Stifel Healthcare Conference TranscriptNov 15, 2022
- Lyra Therapeutics Inc at H C Wainwright Global Investment Conference (Virtual) TranscriptSep 14, 2022
- Lyra Therapeutics Inc Annual Shareholders Meeting TranscriptJun 16, 2022
- Lyra Therapeutics Inc at Jefferies Healthcare Conference TranscriptJun 09, 2022
- Lyra Therapeutics Inc at William Blair Growth Stock Conference TranscriptJun 06, 2022
- Lyra Therapeutics Inc at Bank of America Healthcare Conference TranscriptMay 12, 2022
- Q3 2021 Lyra Therapeutics Inc Earnings Call TranscriptNov 09, 2021$6.79 (-3.69%)Earnings
- Q2 2021 Lyra Therapeutics Inc Earnings Call TranscriptAug 09, 2021$6.69 (-4.02%)Earnings
- Lyra Therapeutics Inc at William Blair Biotech Focus Conference (Virtual) TranscriptJul 15, 2021
- Lyra Therapeutics Inc at Bank of America Global Research Healthcare Conference (Virtual) TranscriptMay 13, 2021
- Q4 2020 Lyra Therapeutics Inc Earnings Call TranscriptMar 09, 2021$14.6 (+2.17%)Earnings
- Lyra Therapeutics Inc in Maria Palasis & Strong Leadership in HealthTech TranscriptOct 08, 2020
- Q2 2020 Lyra Therapeutics Inc Earnings Call TranscriptAug 05, 2020$13.96 (+1.68%)Earnings
Lyra Therapeutics Inc at HC Wainwright Investment Conference - New York Transcript
All right. Welcome back, everyone, to H.C. Wainwright's 25th Annual Global Investment Conference. My name is Matthew Caufield. I'm a biotechnology equity research analyst here at HCW.
We're very pleased to now have a fireside chat with Lyra Therapeutics, and I'd like to welcome President and CEO Maria Palasis. Thank you very much for being here.
Thank you, Matthew. It's great to be here.
Questions & Answers
Excellent. Well, we're very excited. Obviously, the team recently had their Phase 2 positive top line for the BEACON trial for candidate LYR-220 in post-surgical CRS. So maybe just before we dive into that topic and kind of all the progress you guys have been up to, maybe just, at a high level, you could tell us a little bit about your company's strategic focus, sort of your disease focus, the unmet need.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)